Core Viewpoint - The U.S. Department of Commerce announced the final ruling on the anti-dumping and countervailing duty investigation regarding Chinese erythritol, imposing a countervailing duty rate of 8.63% on the company, with a significant increase in the overall tax rate for direct exports to the U.S. [1] Group 1 - The final countervailing duty rate for the company is set at 8.63%, while the overall tax rate for direct exports to the U.S. is 184.26%, which is a reduction of 266.38% from the preliminary ruling [1] - The company did not qualify for separate rates, but exports through specific channels may be subject to a deposit rate of 84.95% [1] - The U.S. International Trade Commission is expected to announce its determination on industry damage in March, which could lead to the issuance of tax orders by the Department of Commerce if the determination is affirmative [1] Group 2 - The "double-reverse" investigation has created substantial pressure on the company's business operations in the U.S. [1] - In response to these challenges, the company is implementing measures such as strengthening cooperation with specific channels, diversifying its product offerings, and expanding its domestic and international market presence [1]

Core Viewpoint - The company, San Yuan Bio, has received a renewed certification as a high-tech enterprise from multiple governmental bodies in Shandong Province, indicating its continued status in the high-tech sector [2]. Group 1 - The announcement was made on February 9, highlighting the company's successful re-certification process [2]. - The re-certification follows the expiration of the previous high-tech enterprise certificate held by the company [2].

Core Viewpoint - The U.S. Department of Commerce announced the final ruling on anti-dumping and countervailing investigations regarding erythritol products originating from China, which significantly impacts the company's export conditions and market competitiveness [1] Summary by Category Anti-Dumping and Countervailing Duties - The company, as a mandatory respondent, faces a countervailing duty rate of 8.63% [1] - Other Chinese manufacturers/exporters are subject to countervailing duty rates ranging from 4.54% to 8.12% [1] - The company did not qualify for separate rates as an exporter, resulting in a unified anti-dumping tax rate of 184.26%, a reduction of 266.38% from the preliminary ruling of 450.64% [1] Export Conditions - When exporting through a specific separate rate channel (SRA), the company can apply an anti-dumping cash deposit rate of 84.95% [1] - The combined execution tax rate for exports to the U.S. through this specific channel is 93.58%, which includes the anti-dumping cash deposit rate and the countervailing duty rate [1] Market Impact - The high tax rate is expected to weaken the company's cost competitiveness in the U.S. market [1] - The company faces risks of reduced orders and loss of market share for the affected products due to these duties [1]

此次美国商务部公布的为反倾销、反补贴调查终裁结果，美国国际贸易委员会（ITC）预计将于2026年 3月公布产业损害最终裁定。若ITC做出肯定性裁定，美国商务部将正式发布反倾销、反补贴税令。本 次"双反"调查对公司在美市场的业务拓展产生了实质性压力。鉴于公司通过前述特定渠道（SRA）出口 美国的综合执行税率（反倾销现金保证金率84.95%+反补贴税率8.63%）仍达到93.58%，该税率水平预 计将削弱公司相关产品在美市场的成本竞争优势，公司面临涉案产品订单缩减及市场份额流失的风险。 目前，公司正在采取多种措施积极应对。首先，在严守贸易合规的前提下，公司将加强与具备特定单独 税率资格的贸易渠道（SRA）合作，充分利用相对较低的综合税率通道维持美国市场的业务连续性。同 时，公司将充分利用前述产品排除条款，加大对美出口非涉案的小包装复配糖产品，并积极推广莱鲍迪 苷M、阿洛酮糖及塔格糖等非涉案新产品，通过差异化布局提升出口业务的抗风险能力。 2026年2月4日，美国商务部公布了关于本次赤藓糖醇反倾销调查终裁结果。公司作为出口商未能获得分 别税率资格，直接向美国出口时适用184.26%的中国全国统一税率，较初裁（450 ...

Core Viewpoint - Sanmiao Biotechnology (301206.SZ) has received the "High-tech Enterprise Certificate" from multiple governmental bodies in Shandong Province, indicating a successful re-certification after the expiration of its previous certificate [1] Group 1 - The company has been recognized as a high-tech enterprise, which may enhance its credibility and competitive advantage in the biotechnology sector [1] - The re-certification process was conducted by the Shandong Provincial Department of Science and Technology, the Shandong Provincial Department of Industry and Information Technology, the Shandong Provincial Department of Finance, and the State Taxation Administration of Shandong Province [1]

证券代码：301206 证券简称：三元生物 公告编号：2026-010 山东三元生物科技股份有限公司 关于继续使用暂时闲置超募资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2026 年 2 月 4 日 召开了第五届董事会第十一次会议，会议审议通过了《关于继续使用暂时闲置超 募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超募资金 安全使用的前提下，拟继续使用不超过 60,000 万元人民币暂时闲置超募资金进 行现金管理。使用期限自公司第五届董事会第十一次会议审议通过之日起 12 个 月内有效，在上述投资额度和使用期限内资金可滚动使用。本次公司继续使用暂 时闲置超募资金进行现金管理属于董事会审议权限范围内事项，无需提交股东会 审议。公司授权管理层在上述额度范围及期限内行使投资决策、签署相关文件等 事宜，具体事项由公司财务部负责组织实施。具体内容详见公司于 2026 年 2 月 5 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于继续使用暂时闲置超募资 ...

（450.64%）降低266.38%。公司作为生产商通过特定单独税率渠道向美国出口时，可适用84.95%的反 倾销现金保证金率。鉴于公司通过前述特定渠道（SRA）出口美国的综合执行税率（反倾销现金保证金 率84.95%+反补贴税率8.63%）仍达到93.58%，该税率水平预计将削弱公司相关产品在美市场的成本竞 争优势，公司面临涉案产品订单缩减及市场份额流失的风险。 每经AI快讯，2月9日，三元生物（301206）(301206.SZ)公告称，美国商务部于2026年2月4日公布对原 产于中国的赤藓糖醇产品反倾销、反补贴调查的最终裁定结果。公司作为强制应诉企业，最终裁定反补 贴税率为8.63%。中国其他生产商/出口商适用的反补贴税率为4.54%~8.12%。反倾销方面，公司作为出 口商未能获得分别税率资格，直接向美国出口时适用184.26%的中国全国统一税率，较初裁 ...

Core Viewpoint - The U.S. Department of Commerce has issued final rulings on anti-dumping and countervailing duties for erythritol products from China, significantly impacting the company's market operations in the U.S. [1][2] Group 1: Final Rulings - The final countervailing duty rate for the company is set at 8.63%, while other Chinese producers/exporters face rates between 4.54% and 8.12% [1] - The final anti-dumping duty for the company is 184.26%, a reduction of 266.38% from the preliminary rate of 450.64% [1] - The company can export through a specific separate rate channel (SRA) with an anti-dumping cash deposit rate of 84.95%, while other qualified producers/exporters have rates between 84.86% and 84.95% [1] Group 2: Market Impact and Response - The dual investigation ("double reverse") poses substantial pressure on the company's business expansion in the U.S. market [2] - The combined effective tax rate for exports through the SRA channel is 93.58%, which is expected to weaken the company's cost competitiveness in the U.S. market [2] - The company is taking measures to mitigate risks, including strengthening cooperation with trade channels that have specific separate rate qualifications and promoting non-involved new products to enhance export resilience [2]

证券代码：301206 证券简称：三元生物 公告编号：2026-008 山东三元生物科技股份有限公司 本次系公司持有的原高新技术企业证书有效期满后进行的重新认定。根据国 家有关规定，公司自本次通过高新技术企业认定起连续三年（即 2025 年度至 2027 年度）继续享受国家关于高新技术企业的相关税收优惠政策，即按照 15%的税率 缴纳企业所得税。 公司再次通过国家高新技术企业认定，有利于降低企业税负，公司 2025 年 已按照 15%的企业所得税税率进行纳税申报及预缴，本次高新技术企业的重新认 定事项不影响公司 2025 年度的相关财务数据。 关于公司通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本信息 山东三元生物科技股份有限公司（以下简称"公司"）近日收到山东省科学 技术厅、山东省工业和信息化厅、山东省财政厅、国家税务总局山东省税务局联 合颁发的《高新技术企业证书》，具体信息如下： 企业名称：山东三元生物科技股份有限公司 证书编号：GR202537002765 发证时间：2025 年 12 月 8 日 二、对公司经营 ...

证券代码：301206 证券简称：三元生物 公告编号：2026-009 山东三元生物科技股份有限公司 关于美国对中国赤藓糖醇反倾销、反补贴调查终裁结果 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于近日获悉，美国商 务部于 2026 年 2 月 4 日签署并公布了对原产于中国的赤藓糖醇产品反倾销、反 补贴（以下简称"双反"）调查的最终裁定结果。上述终裁结果自在美国《联邦 公报》正式刊登之日起生效适用。现将具体情况公告如下： 2026 年 2 月 4 日，美国商务部公布了关于本次赤藓糖醇反倾销调查终裁结 果。公司作为出口商未能获得分别税率资格，直接向美国出口时适用 184.26%的 中国全国统一税率，较初裁（450.64%）降低 266.38%。公司作为生产商通过特 定单独税率渠道（SRA，即已获得分别税率资格的出口商组合）向美国出口时， 可适用 84.95% 的反倾销现金保证金率。中国其他获得分别税率资格的生产商/ 出口商适用的反倾销现金保证金率为 84.86% - 84.95%；未获得分别税率资格的 ...